Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Lannett co inc symbols : Snynf save search
LANNETT SHARES UPDATE
Published: 2023-04-04 (Crawled : 11:00) - prnewswire.com
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: 3.93%
H: 0.0%
C: -47.57%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
update
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN INJECTOR DELIVERY DEVICE TO BE USED FOR ITS INSULIN GLARGINE AND INSULIN ASPART DEVELOPMENT PROGRAM
Published: 2022-11-07 (Crawled : 19:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.01%
H: 0.88%
C: 0.88%
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: 2.7%
H: 5.82%
C: 5.33%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: 0.0%
patent device glargine program insulin
LANNETT ANNOUNCES SUBJECT DOSING COMPLETE FOR PIVOTAL CLINICAL TRIAL OF BIOSIMILAR INSULIN GLARGINE
Published: 2022-08-31 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.75%
H: 1.98%
C: 1.98%
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: 0.84%
H: 2.36%
C: 1.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
biosimilar glargine trial insulin
LANNETT REPORTS FISCAL 2022 FOURTH-QUARTER, FULL-YEAR FINANCIAL RESULTS
Published: 2022-08-24 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -4.66%
H: 0.0%
C: -1.69%
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: -2.05%
H: 9.05%
C: 7.78%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.48%
H: 0.0%
C: 0.0%
results
LANNETT PROVIDES UPDATE ON PIVOTAL CLINICAL TRIAL FOR BIOSIMILAR INSULIN GLARGINE
Published: 2022-06-01 (Crawled : 12:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.33%
H: 2.59%
C: 2.59%
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: -0.92%
H: 1.85%
C: -8.33%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
biosimilar glargine trial insulin
Lannett Initiates Pivotal Clinical Trial For Biosimilar Insulin Glargine
Published: 2022-03-29 (Crawled : 12:00) - biospace.com/
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: -2.51%
H: 9.62%
C: 5.76%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
trial insulin glargine biosimilar lantus
LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
Published: 2022-01-21 (Crawled : 12:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.67%
H: 0.65%
C: 0.65%
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: -0.63%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
new drug fda application drug insulin biosimilar glargine
LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
Published: 2021-12-20 (Crawled : 12:30) - biospace.com/
LCI | $0.6855 0.0% 19K
|
Health Technology
|
| O: -2.23%
H: 1.56%
C: -2.86%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.59%
H: 0.18%
C: -0.2%
new drug application drug insulin submission biosimilar glargine
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.